Blood disease protects against malaria in an unexpected way

Children with an inherited blood disorder called alpha thalassemia make unusually small red blood cells that mostly cause a mild form of anemia. Now, researchers have discovered that this disorder has a benefit—it can protect children against one of the world’s greatest killers, malaria, according to a new study.

“We made the surprising finding that packaging your hemoglobin in smaller amounts in more cells is an advantage against malaria,” says Karen Day, Ph.D., Professor and Chairman of the Department of Medical Parasitology at NYU School of Medicine, who led the research with colleagues at the University of Oxford. Hemoglobin is the oxygen-carrying protein in red blood cells.

The new research shows how children with a mild form of alpha thalassemia are protected against life-threatening malarial anemia. The study, published in the March issue of the journal PLoS Medicine, proposes an answer to a biological puzzle that first emerged more than 50 years ago.

Some 800 children living in Papua, New Guinea, participated in the study. Malaria is endemic in Papua New Guinea and 68 percent of children living there have alpha thalassemia. Dr. Day and her then-Ph D. student Freya J.I. Fowkes, and colleagues from the University of Oxford, Papua New Guinea Institute of Medical Research, and Swansea University, show that an attack of severe malaria causes the loss of one-third to one-half of the total number of red blood cells, which number in the trillions per liter of blood. Children with mild alpha thalassemia tolerated this massive loss because they started out with 10 to 20 percent more red blood cells than unaffected children.

“It is really remarkable and so simple. Children with alpha thalassemia have adapted to the loss of red blood cells associated with malarial disease by making more of these cells with less hemoglobin,” says Dr. Day. “So, these children do better because they end up with more hemoglobin overall when they have a malaria attack compared to normal children,” says Dr. Day.

Malaria has been a scourge for thousands of years. The parasite causing the disease spends part of its life inside human red blood cells, which are eventually destroyed. Severe anemia occurs in some children with malaria when blood cell loss leads to hemoglobin levels of less than 50 grams per liter.

Malaria afflicts hundreds of millions of people, causing up to 2 million deaths every year in Africa and Asia. Many of its victims are young children. In regions of the world where malaria is endemic, mutations have arisen in human populations that allow people to survive. Sickle cell trait, for example, protects against malaria.

Nearly sixty years ago the renowned evolutionary biologist J.B.S.Haldane postulated that the thalassemias were common in human populations because they protected against malaria. Alpha thalassemia is common in Asia, the Mediterranean and Melanesia where malaria is or was prevalent. In the mid 1990s researchers working on the north coast of Papua New Guinea proved that children with mild alpha thalassemia, who inherit mutations in the “alpha” part of hemoglobin genes from each parent, were protected against malaria. These children were 60 percent less likely to get severe malarial anemia than normal children, however the mechanism of such protection was unclear.

Dr. Day and colleagues based their new study on this same population of children. “We are proposing an unexpected mechanism of protection against severe malarial anemia” says Dr. Day. “We show that alpha thalassemia is giving the child a hematological advantage by making more red blood cells.

According to the National Human Genome Research Institute, part of the National Institutes of Health, most individuals with alpha thalassemia have milder forms of the disease, with varying degrees of anemia. The most severe form of alpha thalassemia, which mainly affects individuals of Southeast Asian, Chinese and Filipino ancestry, results in fetal or newborn death.

Source: New York University Medical Center

Related stories:

Elusive protein protects malaria parasite from heme
Researchers at the Virginia Bioinformatics Institute at Virginia Tech have identified Heme Detoxification Protein, a unique protein encoded in the malaria genome that represents a potential target for developing new malaria drugs.
Engineers create new technique for malaria diagnosis
Researchers from the Universities of Exeter and Coventry have developed the first new technique for diagnosing malaria able to challenge the rapid diagnostic tests (RDTs) currently used in the field.
Elusive protein protects malaria parasite from heme
Researchers at the Virginia Bioinformatics Institute (VBI) at Virginia Tech have identified Heme Detoxification Protein (HDP), a unique protein encoded in the malaria genome that represents a potential target for developing new malaria drugs.
Discovery to hasten new malaria treatments, vaccines for children
April 25 is World Malaria Day 2008 and despite the grim statistics out of Africa there’s cause for celebration. Florida State University biologists have discovered an autoimmune-like response in blood drawn from malaria-infected African children that helps to explain why existing DNA-based anti-malaria vaccines have repeatedly failed to protect them.
Swiss researchers develop antibody test
ETH Zurich professor Peter Seeberger has been working on a sugar-based malaria vaccine for years. The new test takes him one important step closer to his goal. The malaria pathogen plasmodium falciparum carries poisonous sugar molecules – called GPIs for short – on its surface that are able to be individually identified. Professor See-berger’s research team is now developing a new method that demonstrates that the malaria pathogen’s toxic sugar molecules trigger a specific immune reaction in adults.
Supplementary approach to malaria
Could a simple vitamin A and zinc supplement help protect young children from malaria? A randomized double blind trial reported in the open access publication, Nutrition Journal, would suggest the answer is yes.
Malaria vaccine trials begin using 'chimpanzee virus'
Trials are underway, funded by the Wellcome Trust, for a new vaccine to combat the most deadly form of malaria. For the first time ever, researchers will use a virus found in chimpanzees to boost the efficacy of the vaccine. The trials will take place at the University of Oxford's Jenner Institute, led by its Director, Professor Adrian Hill.
Early promising results in malaria vaccine trial in Mali
A small clinical trial conducted by an international team of researchers in Mali has found that a candidate malaria vaccine was safe and elicited strong immune responses in the 40 Malian adults who received it.

News discussion:

Medicine & Health news